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In vitro Evaluation of Antibiotic Lock Technique for the Treatment 
of Candida albicans, C. glabrata, and C. tropicalis Biofilms
Candidaemia associated with intravascular catheter-associated infections is of great 
concern due to the resulting high morbidity and mortality. The antibiotic lock technique 
(ALT) was previously introduced to treat catheter-associated bacterial infections without 
removal of catheter. So far, the efficacy of ALT against Candida infections has not been 
rigorously evaluated. We investigated in vitro activity of ALT against Candida biofilms 
formed by C. albicans, C. glabrata, and C. tropicalis using five antifungal agents 
(caspofungin, amphotericin B, itraconazole, fluconazole, and voriconazole). The 
effectiveness of antifungal treatment was assayed by monitoring viable cell counts after 
exposure to 1 mg/mL solutions of each antibiotic. Fluconazole, itraconazole, and 
voriconazole eliminated detectable viability in the biofilms of all Candida species within 7, 
10, and 14 days, respectively, while caspofungin and amphotericin B did not completely 
kill fungi in C. albicans and C. glabrata biofilms within 14 days. For C. tropicalis biofilm, 
caspofungin lock achieved eradication more rapidly than amphotericin B and three azoles. 
Our study suggests that azoles may be useful ALT agents in the treatment of catheter-
related candidemia.
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INTRODUCTION
Candida is one of the most common causes of nosocomial in-
fections (1). In particular, the ability of Candida spp. to form the 
surface adherent growths termed biofilms is an important attri-
bute in catheter-related infections, which increase mortality, 
morbidity, and medical costs. The current recommendation for 
catheter- or device-related infections caused by Candida spp.  
is the removal and replacement of the infected device (2). How-
ever, the process is accompanied by increased costs. In addition, 
in many patients with catheter-related infection, the removal of 
the infected device is sometimes difficult or has procedure-re-
lated risks (3). As an alternative, although the removal of the 
catheter is most appropriate for catheter-related candidemia, 
the antibiotic lock technique (ALT) has been recommended for 
the prevention and treatment of catheter-related infections in 
specific situations by the Infectious Diseases Society of America 
(IDSA) and the Centers for Disease Control and Prevention (CDC) 
(2, 4). In the ALT, a concentrated antibiotic solution is instilled 
into the central venous catheter (CVC) lumen and allowed to 
dwell (“lock”) for several hours or days. So far, a few antifungal 
agents including caspofungin, micafungin, amphotericin B, and 
fluconazole have been evaluated for their efficacies in ALT for 
the treatment of infections mainly caused by C. albicans (5-7). 
However, other clinically important Candida species such as C. 
glabrata and C. tropicalis have been rarely tested. 
  In previous studies, we demonstrated the in vitro effectiveness 
of ALT for the treatment of catheter-related infections by staph-
ylococci, Pseudomonas aeruginosa, and Klebsiella pneumoniae 
(8, 9). The results of our studies as well as those by other investi-
gators have suggested that selection of antimicrobial agents, 
their concentration, and their treatment duration depending 
on the organisms are important (10). In this study, we exam-
ined the in vitro activity of ALT to determine the adequate anti-
fungal agents and duration of locking therapy for treatment of 
fungal biofilms formed by C. albicans, C. glabrata, and C. tropi-
calis. 
 
MATERIALS AND METHODS
Strain
C. albicans SMC154, C. glabrata SMC128, and C. tropicalis SMC297 
were isolated from catheterized blood of patients with underly-
ing diseases such as diabetes mellitus-complicated foot infec-Ko KS, et al.  •  Treatment of Candida Biofilms 
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tion (C. albicans SMC154), prostate cancer (C. glabrata SMC128), 
and hypoxic brain damage after cardiac arrest (C. tropicalis 
SMC297). All strains were confirmed to be biofilm-forming by 
using 96-well plate.
Planktonic minimal inhibitory concentrations (MICs)
Five antifungal agents commonly used to treat candidiasis were 
selected for this study: caspofungin (Merck, Basal, Switzerland), 
amphotericin B (Sigma-Aldrich, St. Louis, MO, USA), flucon-
azole, voriconazole (both from Pfizer, New York, NY, USA), and 
itraconazole (Janssen-Ortho, Toronto, ON, Canada). Caspofun-
gin, fluconazole, and voriconazole were solubilized in sterile 
water, and amphotericin B and itraconazole were solubilized in 
dimethyl sulfoxide. MICs of the free-floating (planktonic) fungi 
were determined by the broth microdilution method according 
to the Clinical and Laboratory Standards Institute (11). MICs were 
determined using Roswell Park Memorial Institute (RPMI1640) 
medium and Yeast nirtogen base medium supplemented with 
50 mM glucose (YNB-Glc) to maintain the experimental condi-
tions related to the biofilm assay. C. parapsilosis ATCC 22019 
was used as a quality control strain. 
Sessile MICs
The MICs of the adherent (sessile) biofilm fungi (SMICs) were 
determined using the 2,3-bis(2–methoxy–4–nitro–5-sulfophe-
nyl)-5-[(phenylamino)carbonyl]-2H-tetrazolium hydroxide 
(XTT) reduction assay (12, 13). All drugs were prepared in a se-
ries of two-fold dilutions, ranging in concentration from 4-256 
mg/L. The inhibitory effects against biofilms were measured as 
the absorbance at 492 nm by using a VERSAmax Tunable mi-
croplate reader (Molecular Devices, Sunnyvale, CA, USA). The 
SMIC50 and SMIC80 for Candida biofilms were defined as the 
lowest drug concentration with a 50% and 80% reduction, respec-
tively, in absorbance compared with the drug-free control. 
Biofilm formation
A polyurethane (PU) sheet prepared as previously described was 
cut into 1×1 cm pieces (thickness, 0.3 mm) and was sterilized 
with ethylene oxide gas (14). Candida strains were grown on 
Sabouraud dextrose agar (SDA) plates at 37°C for 48 hr. A cell 
suspension was prepared and diluted with YNB-Glc, to yield a 
final inoculum of about 1×10
7 colony forming units (CFU)/mL. 
Four sheets of the PU squares were placed in 10 mL of a cell sus-
pension in YNB-Glc, prior to incubation with shaking at 75 rpm 
and 37°C for 5 days to allow biofilm formation. 
 
In vitro ALT model
In vitro ALT was performed according to a previously described 
method with minor modification (8). Briefly, after 5 days of in-
cubation, the PU pieces were washed twice with phosphate-
buffered saline (PBS) to remove nonadherent cells. The colo-
nized squares of PU were transferred to YNB-Glc containing 1 
mg/mL of the individual antifungal agents. Drug-free YNB-Glc 
was used as a control for each experiment. The biofilm killing 
activities of each antifungal agent were assayed after lock peri-
ods of 1, 3, 5, 7, 10, or 14 days. Antifungal lock solutions were re-
placed every 2 days. Biofilm eradication was evaluated by the 
determination of viable cell counts. The PU pieces were moved 
into new 50 mL tubes and washed twice with 10 mL of sterile 
PBS to remove planktonic fungi and drug residue. Then, the ses-
sile bacteria were recovered to complete release of adherent yeast 
by high-speed vortexing in 3 mL of sterile PBS, followed by son-
ication using a VCX-400 sonicator (Sonics & Materials, Danbury, 
CT, USA) using conditions of 120 s, 30% cycle, 3.5 s pulses. The 
number of viable cells was counted in 10-fold serial dilutions 
following plating on SDA and incubation. Each experiment was 
repeated three times.
 
RESULTS
MICs and SMICs 
The MICs and SMICs of the five antifungal agents tested against 
the biofilms formed by three Candida spp. strains are shown in 
Table 1. With regard to MIC, all strains were susceptible to all the 
tested antifungal agents. However, C. albicans SMC154 showed 
a paradoxical growth effect for caspofungin, as growth in the pres-
ence of caspofungin concentrations above the MIC was observed, 
in agreement with previous observations (15). In the XTT reduc-
tion assay, the biofilms of the three Candida spp. displayed re-
sistance to all tested antifungal agents. All antifungal agents ex-
cept amphotericin B showed high SMICs for all strains.
Table 1. MICs (mg/L) and SMICs (mg/L) of antifungal agents for C. albicans, C. glabrata, and C. tropicalis
Antifungal agents
C. albicans SMC154 C. glabrata SMC128 C. tropicalis SMC297
MIC SMIC MIC SMIC MIC SMIC
Caspofungin    0.06* >256/>256   0.06 >256/>256   0.25  >256/>256
Amphotericin B 0.5 16/32 0.5 32/32 0.5   4/16
Itraconazole ≤0.03    256/>256 ≤0.03   128/>256   0.06 >256/>256
Fluconazole   0.25 >256/>256   0.25   128/>256              1 >256/>256
Voriconazole ≤0.03 >256/>256 ≤0.03 >256/>256   0.06 >256/>256
*Parodoxical growth effect.
MIC, minimal inhibitory concentration; SMIC, sessile minimal inhibitory concentration (SMIC50/SMIC80).Ko KS, et al.  •  Treatment of Candida Biofilms 
1724   http://jkms.org DOI: 10.3346/jkms.2010.25.12.1722
Effect of ALT
Fig. 1 displays the relative ALT effectiveness of the five antifun-
gal agents against biofilms formed by C. albicans, C. glabrata, 
and C. tropicalis strains. Initial biofilm viable concentrations of 
each strain after 5 day incubation was 7.75±1.75×10
5 CFU/cm
2 
for C. albicans SMC154, 1.32±0.43×10
6 CFU/cm
2 for C. glabrata 
SMC128, and 1.14±0.98×10
5 CFU/cm
2 for C. tropicalis SMC297. 
For C. albicans SMC154, the PU films were sterilized within 10, 
7, and 14 days of exposure to itraconazole, fluconazole, and vori-
conazole, respectively (Fig. 1A). However, 1 mg/mL of caspofun-
gin and amphotericin B did not eliminate C. albicans SMC154 
within 14 days. C. glabrata SMC128 was also completely eradi-
cated by azoles (Fig. 1B). Itraconazole was the most effective 
against C. glabrata as biofilms were eradicated within 3 days. 
Fluconazole and voriconazole eliminated viable fungi in C. gla-
brata biofilms within 5 and 7 days, respectively. However, C. gla-
brata SMC128 was not completely killed by 1 mg/mL of caspo-
fungin and amphotericin B. Although about 90% of C. glabrata 
SMC128 sessile populations had been killed at 10 days, re-growth 
was detected at 14 days (Fig. 1B). Caspofungin showed the most 
efficiency in treating C. tropicalis biofilms as it eliminated detect-
able viability removed within 5 days (Fig. 1C). The three azole 
agents (itraconazole, fluconazole, and voriconazole) also re-
moved C. tropicalis SMC297 within 7 or 10 days. 
DISCUSSION
Use of indwelling medical devices such as CVCs may increase 
the risk of infection due to formation of biofilms. Such infections 
associated with the biofilms results in significant mortality and 
morbidity, prolong hospitalization, and increase medical costs. 
Currently, removal of the catheter is the most effective treatment 
for catheter-related infections, especially in patients with severe 
sepsis or septic shock. However, the catheter might be retained 
in patients with stable condition to avoid catheter replacement. 
As a conservative strategy, ALT is recommended as an alterna-
tive option for catheter-related infections (2, 10). Although cath-
eter-related infections are the most frequently associated with 
coagulase-negative staphylococci and Staphylococcus aureus, 
other pathogens such as Gram-negative bacilli and Candida 
spp. can also be involved (10, 16). Although some in vitro and 
in vivo studies have evaluated the efficacy of ALT for Candida 
spp. reliable experimental data on the selection of effective an-
tifungal agents and duration time for ALT have not been suffi-
cient (3, 5, 7, 13, 17).
  Presently, the azole compounds itraconazole, fluconazole, 
and voriconazole were found to be generally superior to caspo-
fungin and amphotericin B in eradication of Candida biofilms. 
While 1 mg/mL of each of the three azole compounds eliminat-
ed viable cells in biofilms formed by all three Candida species 
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Fig. 1. In vitro activities of ALT against biofilms formed by three Candida species. (A) 
C. albicans SMC154, (B) C. glabrata SMC128, and (C) C. tropicalis SMC297.  Ko KS, et al.  •  Treatment of Candida Biofilms 
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within 14 days, caspofungin and amphotericin B did not. While 
caspofungin was most effective to treat C. tropicalis biofilms, vi-
able cells were detected in C. albicans and C. glabrata biofilms 
treated were with 1 mg/mL of caspofungin within 14 days. One 
mg/mL of amphotericin B did not completely eliminate viabili-
ty in biofilms formed by any of the three Candida species with-
in 14 days. 
  Although the data is limited, previous studies have reported 
different results from our present data, suggesting that echino-
candins like caspofungin and polyenes like amphotericin B might 
be effective against Candida biofilms (10). Some studies report-
ed that ALT with amphotericin B may be effective in catheter-re-
lated candidemia (2, 3, 18). Cateau et al. (5) and Shuford et al. (7) 
show  ed that caspofungin may be useful in the treatment of C. 
albicans biofilms. Synergistic killing of C. albicans biofilms by 
caspofungin and fluconazole has been reported (19), although 
fluconazole alone is not necessarily effective in eradicating C. 
albicans biofilms (6, 17). Most studies have focused on C. albi-
cans biofilms, to the exclusion of other important Candida spe-
cies such as C. glabrata and C. tropicalis. 
  The different results from the previous studies may be due to 
the method used in determination of biofilm eradication. We 
evaluated the efficacy of ALT antifungal agents based on the re-
duction of viable cell counts as in our previous studies on bac-
terial infections (8, 9). This method of viable cell determination 
has been used in vivo (7, 17). In contrast, several in vitro studies 
monitored the reduction of metabolic activity using XTT (5, 6). 
Although the level of metabolic activity may be positively relat-
ed with viable cell counts (6, 20), 50% reduction of metabolic 
activity was compared in the XTT reduction assay, rather than 
the complete eradication of biofilms as in the viable cell count-
ing method presently used. Caspofungin and amphotericin B 
displayed more than 3-log reduction of viable cell counts (99.9% 
reduction), although they failed to eradicate biofilms complete-
ly in our study. Complete eradication of biofilm organisms may 
be more important in ALT as an alternative option of catheter 
removal to treat catheter-related infections to prevent the relapse 
of infection. In addition, cell density in PU films may be an im-
portant factor contributing to the different ALT results (21). Cell 
density can be influenced by several factors such as growth con-
ditions, strains used in the study, and exposure time in biofilm 
formation. Because the initial cell density of biofilms could not 
be evaluated in the XTT assay, direct comparison of several ALT 
studies might not be possible with regard to cell density. 
  The different results might also reflect limitations in our study 
design. We used only one strain of each Candida species. How-
ever, the efficacy of ALT may strain-dependent as well as spe-
cies-dependent. In addition, we evaluated only one concentra-
tion (1 mg/mL) of antifungal agents. Differing pharmacokinet-
ics and pharmacodynamics of different antifungal agents may 
be reflected in differing optimal concentrations. Unlike previ-
ous studies, the reason that amphotericin B and caspofungin 
showed an inferior effect against C. albicans may be the higher 
MICs and SMICs (Table 1). SMIC50 of caspofungin for C. albicans 
was >256 mg/L in this study, while it was 0.5 mg/L in another 
study (7). In addition, it could not be excluded that C. albicans 
biofilms might not be removed by 1 mg/mL of caspofungin be-
cause of paradoxical effect shown by C. albicans SMC154 for 
caspofungin. Further in vitro and in vivo studies incorporating 
diverse concentrations of antifungal agents against more strains 
are required. In vivo investigations should also be performed 
based on the results of in vitro studies to recommend the appro-
priate guidelines for treatment of catheter-related candidemia.
  Our study suggests that azoles such as itraconazole, flucon-
azole, and voricanazole may be useful ALT agents in the treat-
ment of catheter-related candidemia. Our in vitro results based 
on the treatment with 1 mg/mL of the selected antifungal agents 
demonstrates that fluconazole, itraconazole, and caspofungin 
are most effective in reducing the exposure time of antifungal 
lock solutions for C. albicans, C. glabrata, and C. tropicalis bio-
filems, respectively. 
REFERENCES
1. Han SS, Yim JJ, Yoo CG, Kim YW, Han SK, Shim YS, Lee SM. Clinical 
characteristics and risk factors for nosocomial candidemia in medical 
intensive care units: experience in a single hospital in Korea for 6.6 years. 
J Korean Med Sci 2010; 25: 671-6. 
2. Mermel LA, Allon M, Bouza E, Craven DE, Flynn P, O’Grady NP, Raad 
II, Rijnders BJ, Sherertz RJ, Warren DK. Clinical practice guidelines for 
the diagnosis and management of intravascular catheter-related infec-
tion: 2009 update by the Infectious Diseases Society of America. Clin In-
fect Dis 2009; 49: 1-45.
3. Mukherjee PK, Long L, Kim HG, Ghannoum MA. Amphotericin B lipid 
complex is efficacious in the treatment of Candida albicans biofilms us-
ing a model of catheter-associated Candida biofilms. Int J Antimicrob 
Agents 2009; 33: 149-53. 
4. O’Grady NP, Alexander M, Dellinger EP, Gerberding JL, Heard SO, Maki 
DG, Masur H, McCormick RD, Mermel LA, Pearson ML, Raad II, Ran-
dolph A, Weinstein RA. Guidelines for the prevention of intravascular 
catheter-related infections. Centers for Disease Control and Prevention. 
MMWR Recomm Rep 2002; 51: 1-29.
5. Cateau E, Rodier MH, Imbert C. In vitro efficacies of caspofungin or mi-
cafungin catheter lock solutions on Candida albicans biofilm growth. J 
Antimicrob Chemother 2008; 62: 153-5. 
6. Ramage G, VandeWalle K, Bachmann SP, Wickes BL, López-Ribot JL. 
In vitro pharmacodynamic properties of three antifungal agents against 
performed Candida albicans biofilms determined by time-kill studies. 
Antimicrob Agents Chemother 2002; 46: 3634-6. 
7. Shuford JA, Rouse MS, Piper KE, Steckelberg JM, Patel R. Evaluation of 
caspofungin and amphotericin B deoxycholate against Candida albicans 
biofilms in an experimental intravascular catheter infection model. J In-
fect Dis 2006; 194: 710-3.
8. Lee JY, Ko KS, Peck KR, Oh WS, Song JH. In vitro evaluation of the anti-Ko KS, et al.  •  Treatment of Candida Biofilms 
1726   http://jkms.org DOI: 10.3346/jkms.2010.25.12.1722
biotic lock technique (ALT) for the treatment of catheter-related infections 
caused by staphylococci. J Antimicrob Chemother 2006; 57: 1110-5. 
9. Lee MY, Ko KS, Song JH, Peck KR. In vitro effectiveness of the antibiotic 
lock technique (ALT) for the treatment of catheter-related infections by 
Pseudomonas aeruginosa and Klebsiella pneumoniae. J Antimicrob 
Chemother 2007; 60: 782-7. 
10. Donlan RM. Biofilms on central venous catheters: is eradication possi-
ble? Curr Top Microbiol Immunol 2008; 322: 133-61. 
11. Clinical and Laboratory Standards Institute. Reference method for broth 
dilution antifungal susceptibility testing of yeasts; Approved standard, 
2nd ed. Wayne, PA: Clinical and Laboratory Standards Institute 2008; 
Document No. M27-A2.
12. Hawser SP, Norris H, Jessup CJ, Ghannoum MA. Comparison of a 
2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-5-[(phenylamino)carbonyl]-
2H-tetrazolium hydroxide (XTT) colorimetric method with the stan-
dardized National Committee for Clinical Laboratory Standards meth-
od of testing clinical yeast isolates for susceptibility to antifungal agents. 
J Clin Microbiol 1998; 36: 1450-2. 
13. Kuhn DM, George T, Chandra J, Mukherjee PK, Ghannoum MA. Anti-
fungal susceptibility of Candida biofilms: unique efficacy of amphoteri-
cin B lipid formulations and echinocandins. Antimicrob Agents Che-
mother 2002; 46: 1773-80. 
14. Golomb G, Shpigelman A. Prevention of bacterial colonization on poly-
urethane in vitro by incorporated antibacterial agent. J Biomed Mater 
Res 1991; 25: 937-52. 
15. Melo AS, Colombo AL, Arthington-Skaggs BA. Paradoxical growth effect 
of caspofungin observed on biofilms and planktonic cells of five different 
Candida species. Antimicrob Agents Chemother 2007; 51: 3081-8. 
16. Raad II, Hanna HA. Intravascular catheter-related infections: new hori-
zons and recent advances. Arch Intern Med 2002; 162: 871-8. 
17. Schinabeck MK, Long LA, Hossain MA, Chandra J, Mukherjee PK,   
Mohamed S, Ghannoum MA. Rabbit model of Candida albicans bio-
film infection: liposomal amphotericin B antifungal lock therapy. Anti-
microb Agents Chemother 2004; 48: 1727-32. 
18. Buckler BS, Sams RN, Goei VL, Krishnan KR, Bemis MJ, Parker DP, 
Murray DL. Treatment of central venous catheter fungal infection using 
liposomal amphotericin-B lock therapy. Pediatr Infect Dis J 2008; 27: 
762-4. 
19. Bachmann SP, Ramage G, VandeWalle K , Patterson TF, Wickes BL, 
López-Ribot JL. Antifungal combinations against Candida albicans 
biofilms in vitro. Antimicrob Agents Chemother 2003; 47: 3657-9. 
20. Ferreira JA, Carr JH, Starling CE, De Resende MA, Donlan RM. Biofilm 
formation and the effect of caspofungin on the biofilm structure of Can-
dida species bloodstream isolates. Antimicrob Agents Chemother 2009; 
53: 4377-84.
21. Perumal P, Mekala S, Chaffin WL. Role for cell density in antifungal drug 
resistance in Candida albicans biofilms. Antimicrob Agents Chemother 
2007; 51: 2454-63. 